Form 4: Xenon Pharmaceuticals Director Equity Update

Director Patrick Machado acquired common shares through RSU vesting and received new equity grants.

Summary

• Director Patrick Machado acquired 2,645 common shares on June 1, 2026, following the vesting of restricted share units (RSUs).
• On June 3, 2026, the director was granted 10,507 share options with an exercise price of $53.46, expiring in 2036.
• An additional 1,593 RSUs were granted to the director on June 3, 2026.
• The new equity grants are scheduled to vest on June 1, 2027, or the day before the 2027 annual meeting of shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard vesting schedule for director compensation.

Negatives

• None identified.

Risks

• Potential dilution of existing shareholders upon the future exercise of options and vesting of RSUs.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity transactions.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation activity common in the biotechnology sector, where equity-based incentives are standard for retaining board members.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard practices for mid-cap pharmaceutical companies.
• Vesting schedules tied to annual shareholder meetings are a common governance practice to ensure board continuity.

Stakeholder Impact

• Minor impact on share count due to future equity issuance.

Next Steps

• Vesting of 10,507 share options and 1,593 RSUs on June 1, 2027.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Insider Trading, Form 4, Equity Compensation, Director Compensation